⌘K
Loading ticker…
eXoZymes Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, eXoZymes Inc. Common Stock (EXOZ) has a 3-month relative strength percentile of 60 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 43. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 10.3%, relative volume 1.11×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
60 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
EXOZ is in a stage 4 downtrend, week 4. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -13.7% / -26.8%.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
EXOZ is held by 2 ETFs as of Mar 2026. Top owner: VXF at 0.00% weight, $163K notional.
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $163K |
| VTIVanguard Total Stock Market ETF | 0.00% | $3K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EXOZ Jan avg: -4.59% median: -4.59% win: 0% σ: 0.00% n: 1 2025-02-13 → 2026-05-29 | EXOZ Feb avg: -9.74% median: -9.74% win: 0% σ: 7.31% n: 2 2025-02-13 → 2026-05-29 | EXOZ Mar avg: -26.65% median: -26.65% win: 0% σ: 16.28% n: 2 2025-02-13 → 2026-05-29 | EXOZ Apr avg: 19.08% median: 19.08% win: 100% σ: 19.54% n: 2 2025-02-13 → 2026-05-29 | EXOZ May avg: 10.23% median: 10.23% win: 50% σ: 16.38% n: 2 2025-02-13 → 2026-05-29 | EXOZ Jun avg: -26.27% median: -26.27% win: 0% σ: 0.00% n: 1 2025-02-13 → 2026-05-29 (current) | EXOZ Jul avg: 2.23% median: 2.23% win: 100% σ: 0.00% n: 1 2025-02-13 → 2026-05-29 | EXOZ Aug avg: -3.96% median: -3.96% win: 0% σ: 0.00% n: 1 2025-02-13 → 2026-05-29 | EXOZ Sep avg: 48.74% median: 48.74% win: 100% σ: 0.00% n: 1 2025-02-13 → 2026-05-29 | EXOZ Oct avg: -0.19% median: -0.19% win: 0% σ: 0.00% n: 1 2025-02-13 → 2026-05-29 | EXOZ Nov avg: 10.21% median: 10.21% win: 100% σ: 0.00% n: 1 2025-02-13 → 2026-05-29 | EXOZ Dec avg: -31.32% median: -31.32% win: 0% σ: 0.00% n: 1 2025-02-13 → 2026-05-29 |